Literature DB >> 6866034

Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block.

J S Scott, P J Maddison, P V Taylor, E Esscher, O Scott, R P Skinner.   

Abstract

The relation between congenital heart block and maternal connective-tissue disease was studied by antibody screening of serum samples obtained in connection with 45 cases of isolated congenital complete heart block. Serum was available from 41 mothers (17 who had connective-tissue disease and 24 who were healthy) and 21 children. Thirty-four mothers had antibody to a soluble tissue ribonucleoprotein antigen called Ro(SS-A), which was identified by immunodiffusion. Anti-Ro(SS-A) was found in seven of eight serum samples collected from affected children when they were less than three months old but in none of 13 samples obtained when these children were older. It appears that maternal anti-Ro(SS-A) antibody crosses the placenta and is a marker for risk of congenital complete heart block; its absence from maternal serum suggests that a child is unlikely to be affected. Anti-Ro(SS-A) or a related antibody is probably involved in the pathogenesis of congenital complete heart block.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6866034     DOI: 10.1056/NEJM198307283090403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  77 in total

1.  Value of antenatal echocardiography in high risk patients to diagnose congenital cardiac defects in fetus.

Authors:  A Saxena; S Shrivastava; S S Kothari
Journal:  Indian J Pediatr       Date:  1995 Sep-Oct       Impact factor: 1.967

Review 2.  Systemic lupus erythematosus.

Authors:  M S Klein-Gitelman; M L Miller
Journal:  Indian J Pediatr       Date:  1996 Jul-Aug       Impact factor: 1.967

Review 3.  Autoantibodies against small cytoplasmic ribonucleoproteins: the anti-Ro/SS-A and anti-La/SS-B autoimmune response. A review of autoantibody detection, autoantigen composition, autoantibody-disease associations and possible etiologic mechanisms.

Authors:  J F Meilof
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 4.  Indications for fetal echocardiography.

Authors:  M Small; J A Copel
Journal:  Pediatr Cardiol       Date:  2004 May-Jun       Impact factor: 1.655

5.  Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus.

Authors:  Peter M Izmirly; Amit Saxena; Mimi Y Kim; Dan Wang; Sara K Sahl; Carolina Llanos; Deborah Friedman; Jill P Buyon
Journal:  Circulation       Date:  2011-10-03       Impact factor: 29.690

Review 6.  Anti-Ro antibodies and neonatal lupus.

Authors:  P J Maddison
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

7.  Serum Biomarkers of Inflammation, Fibrosis, and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus.

Authors:  Amit Saxena; Peter M Izmirly; Sung Won Han; Paraskevi Briassouli; Tania L Rivera; Hua Zhong; Deborah M Friedman; Robert M Clancy; Jill P Buyon
Journal:  J Am Coll Cardiol       Date:  2015-08-25       Impact factor: 24.094

8.  Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides.

Authors:  D A Isenberg; C Dudeney; W Williams; A Todd-Pokropek; B D Stollar
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

9.  Advanced atrioventricular block in a neonate with lupus erythematosus and anti-SS-A antibodies.

Authors:  T Shimizu; T Ino; K Nishimoto; M Iwahara; Y Yamashiro; K Yabuta
Journal:  Pediatr Cardiol       Date:  1988       Impact factor: 1.655

10.  Molecular characterization of human Ro/SS-A antigen. Amino terminal sequence of the protein moiety of human Ro/SS-A antigen and immunological activity of a corresponding synthetic peptide.

Authors:  T S Lieu; M M Newkirk; J D Capra; R D Sontheimer
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.